Skip to navigation bar Skip to breadcrumbs Skip to page content
clear place holder
Envelope icon E-mail Updates Teal square Text size:  a A A

Cervical Cancer: Screening

Release Date: August 2018

Recommendation Summary

PopulationRecommendationGrade
(What's This?)
Women aged 21 to 65 years

The USPSTF recommends screening for cervical cancer every 3 years with cervical cytology alone in women aged 21 to 29 years. For women aged 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytology alone, every 5 years with high-risk human papillomavirus (hrHPV) testing alone, or every 5 years with hrHPV testing in combination with cytology (cotesting).

 

See the Clinical Considerations section for the relative benefits and harms of alternative screening strategies for women 21 years or older.

A
Women older than 65 years

The USPSTF recommends against screening for cervical cancer in women older than 65 years who have had adequate prior screening and are not otherwise at high risk for cervical cancer.

 

See the Clinical Considerations section for discussion of adequate prior screening and risk factors that support screening after age 65 years.

D
Women younger than 21 years

The USPSTF recommends against screening for cervical cancer in women younger than 21 years.

D
Women who have had a hysterectomy

The USPSTF recommends against screening for cervical cancer in women who have had a hysterectomy with removal of the cervix and do not have a history of a high-grade precancerous lesion (ie, cervical intraepithelial neoplasia [CIN] grade 2 or 3) or cervical cancer.

D

The first 3 recommendations apply to individuals who have a cervix, regardless of their sexual history or HPV vaccination status. These recommendations do not apply to individuals who have been diagnosed with a high-grade precancerous cervical lesion or cervical cancer. These recommendations also do not apply to individuals with in utero exposure to diethylstilbestrol or those who have a compromised immune system (eg, women living with HIV).

To read the recommendation statement in JAMA, select here.

To read the evidence summary in JAMA, select here.

To read the modeling study in JAMA, select here.

Related Information for Consumers

Related Information for Health Professionals

There is no related information for health professionals.

Clinical Summary

Clinical summaries are one-page documents that provide guidance to primary care clinicians for using recommendations in practice.

This summary is intended for use by primary care clinicians.

 
Current as of: August 2018

Internet Citation: Final Update Summary: Cervical Cancer: Screening. U.S. Preventive Services Task Force. August 2018.
https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/cervical-cancer-screening2

USPSTF Program Office   5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857